DOCSLIB.ORG

The Handbook of Cannabis Therapeutics: from Bench to Bedside

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Handbook of Cannabis Therapeutics: from Bench to Bedside Handbook of Cannabis Therapeutics From Bench to Bedside 9780789030979 Handbook of Cannabis Therapeutics From Bench to Bedside Size: 212 x 152mm Spine size: 26 mm Color pages: Binding: Paperback THE HAWORTH PRESS® Haworth Series in Integrative Healing Ethan Russo Editor The Last Sorcerer: Echoes of the Rainforest by Ethan Russo Professionalism and Ethics in Complementary and Alternative Medicine by John Crellin and Fernando Ania Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential by Franjo Grotenhermen and Ethan Russo Modern Psychology and Ancient Wisdom: Psychological Healing Practices from the World’s Religious Traditions edited by Sharon G. Mijares Complementary and Alternative Medicine: Clinic Design by Robert A. Roush Herbal Voices: American Herbalism Through the Words of American Herbalists by Anne K. Dougherty The Healing Power of Chinese Herbs and Medicinal Recipes by Joseph P. Hou and Youyu Jin Alternative Therapies in the Treatment of Brain Injury and Neurobehavioral Disorders: A Practical Guide edited by Gregory J. Murrey Handbook of Cannabis Therapeutics: From Bench to Bedside edited by Ethan B. Russo and Franjo Grotenhermen Handbook of Cannabis Therapeutics From Bench to Bedside Ethan B. Russo, MD Franjo Grotenhermen, MD Editors Routledge Taylor &. Francis Croup NEW YORK AND LONDON First Published by The Haworth Press, Inc., 10 Alice Street, Binghamton, NY 13904-1580. Transferred to Digital Printing 2010 by Routledge 270 Madison Ave, New York NY 10016 2 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN For more information on this book or to order, visit http://www.haworthpress.com/store/product.asp?sku=5741 or call 1-800-HAWORTH (800-429-6784) in the United States and Canada or (607) 722-5857 outside the United States and Canada or contact [email protected] © 2006 by The Haworth Press, Inc. All rights reserved. No part of this work may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, microfilm, and recording, or by any information storage and retrieval system, without permission in writing from the publisher. PUBLISHER’S NOTE The development, preparation, and publication of this work has been undertaken with great care. However, the Publisher, employees, editors, and agents of The Haworth Press are not responsible for any errors contained herein or for consequences that may ensue from use of materials or infor- mation contained in this work. The Haworth Press is committed to the dissemination of ideas and information according to the highest standards of intellectual freedom and the free exchange of ideas. Statements made and opinions expressed in this publication do not necessarily reflect the views of the Publisher, Directors, management, or staff of The Haworth Press, Inc., or an endorse- ment by them. This book is a compilation of articles previously published in the Journal of Cannabis Therapeu- tics: Studies in Endogenous, Herbal, and Synthetic Cannabinoids, 1(1) (2001): 5-70, 85-88; 1(2) (2001): 15-20; 1(3/4) (2001): 5-16, 103-132; 2(1) (2002): 3-57; 2(2) (2002): 51-79; 2(3/4) (2002): 5-34, 49-81, 103-131, 159-173; 3(1) (2003): 3-51; 3(4) (2003): 163-174; 4(1) (2004): 29-78, pub- lished by The Haworth Press, Inc. This book has been published solely for educational purposes and is not intended to substitute for the medical advice of a treating physician. Medicine is an ever-changing science. As new re- search and clinical experience broaden our knowledge, changes in treatment may be required. While many potential treatment options are made herein, some or all of the options may not be ap- plicable to a particular individual. Therefore, the author, editor, and publisher do not accept respon- sibility in the event of negative consequences incurred as a result of the information presented in this book. We do not claim that this information is necessarily accurate by the rigid scientific and regula- tory standards applied for medical treatment. No warranty, expressed or implied, is furnished with respect to the material contained in this book. The reader is urged to consult with his/her personal physician with respect to the treatment of any medical condition. Photographs by Ethan B. Russo. Medicine bottle from the collection of David Watson, HortaPharm, Amsterdam. Cover design by Kerry E. Mack. Library of Congress Cataloging-in-Publication Data Handbook of cannabis therapeutics : from bench to bedside / Ethan B. Russo, Franjo Grotenhermen, editors. p. cm. “A compilation of selected articles from the Journal of cannabis therapeutics . from 2001 to 2004”—Introd. Includes bibliographical references and index. ISBN-13: 978-0-7890-3096-2 (hard : alk. paper) ISBN-10: 0-7890-3096-9 (hard : alk. paper) ISBN-13: 978-0-7890-3097-9 (soft : alk. paper) ISBN-10: 0-7890-3097-7 (soft : alk. paper) 1. Cannabis—Therapeutic use—History. I. Russo, Ethan. II. Grotenhermen, Franjo. III. Journal of cannabis therapeutics. [DNLM: 1. Cannabis—Collected Works. 2. Phytotherapy—methods—Collected Works. 3. Cannabinoids—history—Collected Works. 4. Cannabinoids—therapeutic use—Collected Works. 5. Plant Extracts—therapeutic use—Collected Works. WB 925 H236 2006] RM666.C266H36 2005 615'.7827—dc22 2005029271 CONTENTS About the Editors xiii Contributors xv Foreword xvii Introduction 1 Franjo Grotenhermen PART I: HISTORICAL NOTES Chapter 1. The Therapeutic Use of Cannabis sativa (L.) in Arabic Medicine 5 Indalecio Lozano Introduction 5 Materials and Methods 6 Results 6 Conclusion 10 Update 12 Chapter 2. Cognoscenti of Cannabis I: Jacques-Joseph Moreau (1804-1884) 13 Ethan B. Russo Chapter 3. Cognoscenti of Cannabis II: Simeon Seth on Cannabis 17 David Deakle Chapter 4. The Medical Use of Cannabis Among the Greeks and Romans 23 James L. Butrica Introduction 23 Absence of Mention 24 The Emergence of Cannabis 25 Appendix I: Passages Discussing Wild Cannabis Possibly Misunderstood As Discussing Domesticated Cannabis 40 Appendix II: Cannabis in Veterinary Medicine 41 Update 42 Chapter 5. A Homelie Herbe: Medicinal Cannabis in Early England 43 Vivienne Crawford Introduction 43 Cannabis History in England 45 The Modern Era 49 Update 51 Chapter 6. Future of Cannabis and Cannabinoids in Therapeutics 53 Ethan B. Russo Introduction 53 New Indications for Cannabinoid Pharmaceuticals 56 Cannabinoids and Neuroprotection 57 Spasmodic Disorders 58 Forbidden Territories 58 Update 63 PART II: PHARMACOLOGY AND PHARMACOKINETICS Chapter 7. Clinical Pharmacokinetics of Cannabinoids 69 Franjo Grotenhermen Introduction 69 Pharmacokinetics of ∆9-THC 74 Absorption 75 Distribution 80 Metabolism 84 Course of Plasma Concentration of THC and Metabolites 87 Elimination 88 Time Effect Relationship 94 Pharmacokinetics of Other Cannabinoids 99 Metabolic Interactions 101 Conclusion 103 Chapter 8. Clinical Pharmacodynamics of Cannabinoids 117 Franjo Grotenhermen Introduction 117 Mechanism of Action 119 Cannabinoid Receptors 121 Endocannabinoids 122 Pharmacological Effects of THC 125 Toxicity 125 Psyche, Cognition and Behavior 127 Central Nervous System and Neurochemistry 128 Circulatory System 130 Some Other Organ Systems and Effects 131 Pharmacological Activity of THC Metabolites 133 Pharmacological Effects of Other Cannabinoids 135 Tolerance and Dependency 138 Therapeutic Uses 139 Hierarchy of Therapeutic Effects 140 Basic Research Stage 141 Drug Interactions 143 Conclusions 144 Update 165 Chapter 9. Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? 171 John M. McPartland Ethan B. Russo Introduction 171 Materials and Methods 172 Results and Discussion 172 Cannabinoids 173 Terpenoids 178 Flavonoids 187 Conclusions 190 Update 201 PART III: ENDOCANNABINOIDS AND CANNABINOID RECEPTORS Chapter 10. The Endocannabinoid System: Can It Contribute to Cannabis Therapeutics? 207 Vincenzo Di Marzo The Endocannabinoid System 207 Endocannabinoid Pharmacology: More Than Meets the Eye 209 Levels of Endocannabinoids in Tissues: Physiology and Pathology 211 New Drugs From the Endocannabinoid System: Curative or Palliative? 216 Update 225 Chapter 11. Cannabinoids and Feeding: The Role of the Endogenous Cannabinoid System As a Trigger for Newborn Suckling 227 Ester Fride Interactions of the Endocannabinoid System with Hormones Regulating Food Intake 228 Endocannabinoids in Food Substances 229 Developmental Aspects of the Endocannabinoid-CB1 Receptor System 230 Blockade of CB1 Receptors in Newborn Mice 231 Mechanisms of the CB1 Receptor Blockade-Induced Growth-Stunting Effects 233 Conclusions 234 Update 238 PART IV: MEDICINAL USES Chapter 12. Marijuana (Cannabis) As Medicine 243 Leo E. Hollister Introduction 243 Indications with Evidence for Medical Efficacy 245 Indications with Sparse Evidence of Efficacy 253 Discussion 257 Conclusion 258 Update 263 Chapter 13. Effects of Smoked Cannabis and Oral 9-Tetrahydrocannabinol on Nausea and Emesis After Cancer Chemotherapy: A Review of State Clinical Trials 265 Richard E. Musty Rita Rossi Tennessee 266 Michigan 267 Georgia 268 New Mexico (1983) 270 New Mexico (1984) 271 California 272 New York 273 Discussion 275 Update 278 Chapter 14. Hyperemesis Gravidarum and Clinical Cannabis: To Eat or Not to Eat? 281 Wei-Ni Lin Curry HG, Its Medicalization, and the Survivors 282 Cannabis, Pregnancy, and HG 288 Two Women’s Stories of Using Folk, Alternative Medicine 293 Conclusion 297 Update 302 Chapter 15. Therapeutic Cannabis (Marijuana) As an Antiemetic and Appetite Stimulant in Persons with Acquired Immunodeficiency Syndrome 303 Richard E. Bayer AIDS
Load more

Recommended publications
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • Extracts and Tinctures of Cannabis
    WHO Expert Committee on Drug Dependence Critical Review …………….. Extracts and tinctures of cannabis This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • Cannabinoids in the Pathophysiology of Skin Inflammation
    molecules Review Cannabinoids in the Pathophysiology of Skin Inflammation Cristian Scheau 1 , Ioana Anca Badarau 1, Livia-Gratiela Mihai 1, Andreea-Elena Scheau 2, Daniel Octavian Costache 3, Carolina Constantin 4,5, Daniela Calina 6 , Constantin Caruntu 1,7,*, Raluca Simona Costache 8,* and Ana Caruntu 9,10 1 Department of Physiology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; [email protected] (C.S.); [email protected] (I.A.B.); [email protected] (L.-G.M.) 2 Department of Radiology and Medical Imaging, Fundeni Clinical Institute, 022328 Bucharest, Romania; [email protected] 3 Department of Dermatology, “Carol Davila” Central Military Emergency Hospital, 010825 Bucharest, Romania; [email protected] 4 Immunology Department, ”Victor Babes” National Institute of Pathology, 050096 Bucharest, Romania; [email protected] 5 Department of Pathology, Colentina University Hospital, 020125 Bucharest, Romania 6 Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; [email protected] 7 Department of Dermatology, “Prof. N. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, 011233 Bucharest, Romania 8 Gastroenterology and Internal Medicine Clinic, Carol Davila University Central Emergency Military Hospital, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania 9 Department of Oral and Maxillofacial Surgery, “Carol Davila” Central Military Emergency Hospital, 010825 Bucharest, Romania; [email protected] 10 Faculty of Medicine, “Titu Maiorescu” University, 031593 Bucharest, Romania * Correspondence: [email protected] (C.C.); [email protected] (R.S.C.); Tel.: +40-745-086-978 (C.C.) Academic Editor: Eric J. Downer Received: 30 December 2019; Accepted: 2 February 2020; Published: 4 February 2020 Abstract: Cannabinoids are increasingly-used substances in the treatment of chronic pain, some neuropsychiatric disorders and more recently, skin disorders with an inflammatory component.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • The Razor Wire
    Autumn 2003 Vol. 7 No. 2 The Razor Wire Winter 2004 Nonviolent Offender Relief Act November 5th, 2003 introduced in House Time: 6:45 AM Stratford High School he Federal Prison Bureau Nonviolent Offender Relief Act of 2003, HR 3575, was introduced in the House of Representatives on November 21. Relief in the form of early release eligibility would come to prisoners at least 45 years of age who have served half their sentence, "Get on the ground! Get with no history of violence, or violations of institutional disciplinary regulations. (You will find the on the ground!" an full bill text on page 6.) officer yells as students The bill has been referred to the House Judiciary Committee where members will argue its fall to the floor. merits, listen to varied testimony from pro and con voices, and undoubtedly modify its language. If HR 3575 becomes law as it’s now written, its effects would be significant. Had a parole bill been introduced before, or simultaneously, it would have made comment easier for anyone attempting it formally. Many November Coalition members don’t expect HR 3575 to stand alone, or for very long. Thus, at this time of congressional interest, we encourage support for any bill offering relief to the imprisoned, assistance to former prisoners, and sentencing relief for ‘future drug offenders.’ There are bills in Congress in each broad category. That said, our members should appreciate how relentless pressure over the years has pushed proposed bills for early release into Congressional hearing rooms in 2003-4. This progress is "Hands on your head, evidence of a new era of popular democracy.
    [Show full text]
  • Medical Values in a Commercial Age
    Proceedings of the British Academy, 78, 149-163 Medical Values in a Commercial Age W.F. BYNUM Wellcome Institute for the History of Medicine EVENthe phrase ‘Victorian values’ is a reminder that historians write about themselves as well as the past. A volume with this title has different reverberations for us than it would have had for a historian of Lytton Strachey’s generation, and even the inclusion of a paper on medicine testifies to recent changes in historical perceptions and practice. Neither science nor medicine rated a chapter in G.M. Young’s Early Victorian Britain, and only three decades ago, Walter Houghton’s Victorian Frame of Mind contained but one brief reference to medicine and only cursory material on what is now seen as a much more central Victorian preoccupation: health.1 The army doctor and sanitary reformer Edmund Parkes (1819-1875) was speaking as a Victorian as much as he was as a doctor when he urged young doctors ‘Never [to] think of your life, but always of your health, which alone can make life useful’.2 Parkes’s coupling of health and usefulness was high praise indeed, for usefulness could easily have served alongside Duty, Thrift and Self-Help as a marketable volume by that quintessential Victorian Samuel Smiles, himself of course originally a trained doctor. In fact, an episode in Smiles’s early career points to the theme which I shall discuss here. After a medical Read 13 December 1990. 0The British Academy 1992. G.M. Young (ed.), Early Victorian England, 1830-1865, 2 vols (London, 19h); Walter Houghton, The Victorian Frame of Mind, 1830-1870 (New Haven, 1957).
    [Show full text]
  • Capital, Profession and Medical Technology: Royal College Of
    Medical History, 1997, 41: 150-181 Capital, Profession and Medical Technology: The Electro-Therapeutic Institutes and the Royal College of Physicians, 1888-1922 TAKAHIRO UEYAMA* That it is undesirable that any Fellow or Member of the College should be officially connected with any Company having for its object the treatment of disease for profit. (Resolution of the Royal College of Physicians of London, 25 Oct. 1888.) That subject to the general provisions of Bye-law 190 the College desires so to interpret its Bye-law, Regulations, and Resolutions, as no longer to prohibit the official connection of Fellows and Members with medical institutes, though financed by a company, provided there be no other financial relation than the acceptance of a fixed salary or of fees for medical attendance on a fixed scale, irrespective of the total amount of the profits of the Company. (Resolution of the Royal College of Physicians of London, 1922, replacing the Resolution of 1888.) No Fellow or Member of the College shall be engaged in trade, or dispense medicines, or make any engagement with a Pharmacist [altered from Chemist] or any other person for the supply ofmedicines, or practise Medicine or Surgery in partnership, by deed or otherwise, or be a party to the transfer of patients or of the goodwill of a practice to or from himself for any pecuniary consideration. (Bye-law 178 of the Royal College of Physicians of London, 1922, alterations in italics.)l This paper examines the implications of an historical drama at the Censors' Board of the Royal College of Physicians of London (henceforth RCP) in the late 1880s and 1890s.
    [Show full text]
  • Potential Health Benefits of Cannabis Extracts: a Review Maria Rosana Ramirez
    International Journal of Chemical and Biomedical Science 2016; 2(1): 1-8 Published online March 1, 2016 (http://www.aascit.org/journal/ijcbs) Potential Health Benefits of Cannabis Extracts: A Review Maria Rosana Ramirez CITER-The National Scientific and Technical Research Council (CONICET), Argentine Government, Agency, Argentina Email address [email protected] Citation Maria Rosana Ramirez. Potential Health Benefits of Cannabis Extracts: A Review. International Journal of Chemical and Biomedical Science . Vol. 2, No. 1, 2016, pp. 1-8. Keywords Abstract Non-cannabinoids Compounds, A central tenet underlying the use of plant preparations is that herbs contain many Cannabis Extracts, bioactive compounds. Cannabis contains tetrahydrocannabinols (THC) a primary Bioactivity metabolite with reported psychotropic effects. Therefore, the presence of THC makes controversial the use of Cannabis to treat diseases by which their uses and applications were limited. The question then is: is it possible to use the extracts from Cannabis to treat the diseases related with it use in folk medicine? More recently, the synergistic Received: January 24, 2016 contributions of bioactive constituents have been scientifically demonstrated. We Revised: February 10, 2016 reviewed the literature concerning medical cannabis and its secondary metabolites, Accepted: February 12, 2016 including fraction and total extracts. Scientific evidence shows that secondary metabolites in cannabis may enhance the positive effects of THC a primary metabolite. Other chemical components (cannabinoid and non-cannabinoid) in cannabis or its extracts may reduce THC-induced anxiety, cholinergic deficits, and immunosuppression; which could increase its therapeutic potential. Particular attention will be placed on non- cannabinoid compounds interactions that could produce synergy with respect to treatment of pain, inflammation, epilepsy, fungal and bacterial infections.
    [Show full text]
  • Cannabis Alchemy
    Contents Preface Introduction Chapter One Extraction & Purification of Marijuana & Hashish Oils Chapter Two Isomerization Chapter Three THC Acetate Chapter Four Preparation of Hashish Chapter Five Increasing Potency of Intact Marijuana Flowers Chapter Six Preparation of Oil Capsules Chapter Seven Smoking Oil by Direct Vaporization Chapter Eight Preparation of Translucent (Honey) Oil Chapter Nine Preparation of “Reefers” Chapter Ten High-Volume Extraction Method Chapter Eleven Advanced Refinement Techniques Appendix A Letters Appendix B Solvent Notes Glossary References D. Gold reveals the inner world of marijuana and hashish in CANNABIS ALCHEMY. Accompany the alchemist as he uncovers the secrets of enhancing potency in this informative text. “Cannabis lovers awake and sing! For this is surely no less than a masterwork, a lucid, extraordinarily practical labor of alchemical love and lore.” David Solomon, author of “Marijuana Papers” “This modern classic adds a valid new twist to the ancient art of getting high.” George Andrews, author of “The Book of Grass” Preface The cultivation of marijuana and the refinement of its preparations has concerned alchemists and hedonists on this planet for centuries. Cannabis sativa and Cannabis indica are both powerful allies. The body of the plant itself serves as a link between the physical plane and a host of Spirits of exceptional wisdom and subtlety. When the plant is ingested, these qualities are manifested in the. mind of the worshipper, unlocking the storehouse of Wisdom within and revealing the hidden springs of pleasure. Smoking or eating the leaves or flowers is usually sufficient to bring about the desired state, although it seems inherent in the nature of Man to search for more concentrated forms of the drug that are stronger, more pleasant to ingest, or more desirable in some other way.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • The Pet Issue P12
    M A G A Z I N E BOUTIQUE CANNABIS CULTURE 08 22 HOW CANNABIS CAN HELP YOUR PET Through the consumption of cannabinoids, your pet can receive the same incredible benefits as humans. The Pet Issue p12 Letter From the Editor The Meeting Place for Industry Innovators PUBLISHER CHRISTINA DEGIOVANNI March 20-22, 2017 MANAGING EDITOR JAANA PRALL Oakland Marriott City Center Cannabis 2017 is different than any other event in the market. In addition to its Oakland, CA EDITOR-AT-LARGE MELISSA HUTSELL unique combination of educational programming on both cultivation and busi- ASSISTANT COPY EDITOR MELODY HAYHURST As the legal ness management, it has been developed by cultivators, for cultivators. cannabis GRAPHICS TANYA NORDBERG | NATHAN WELLS industry Join industry leaders, CEOs, executive team members and innovators for 2½ evolves, the need SOCIAL MEDIA MANAGER JESSICA BARFIELD intense days of interactive learning and networking as we move the industry for legitimate COVER SHOT @TREETOPGARDENS_ “cultivation and forward at Cannabis 2017. business management information is at an FEATURED SPEAKERS INCLUDE: CONTRIBUTORS all-time high. Cannabis MOLLY CATE | LESLIE CLARY | ART COSGROVE 2017 provides an BROKKE GEHRING DAVID BONVILLAIN TODD HILL ALLISON EDRINGTON | EMILY HOBELMANN unparalleled education MELISSA HUTSELL | JEFF THE 420 CHEF program that will be SHARON LETTS | PAM LONG | NORA MOUNCE crucial to those who SHANNON PERKINS | ASHLEY PRIEST want to thrive in this JAMES PRIEST | DIANA TRIMBLE industry.” Ken Morrow, Owner, Trichome Technologies PHOTOGRAPHY CANNABIS 2017 CONFERENCE CHAIR PATRICK ANDERSON | 8 MILE FAMILY FARM CEO Founder and CEO Founder/Managing Principal @BAKEDINHUMBOLDT | @COASTALFOGFARMS Dear Reader, FGS Inc.
    [Show full text]